Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide
- PMID: 20002084
- PMCID: PMC2810801
- DOI: 10.1111/j.1365-2125.2009.03536.x
Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide
Abstract
What is already known about this subject: * Patients with Type 2 diabetes are likely to have or to develop renal impairment, which affects the pharmacokinetics of some antidiabetic treatments. * Whether dosing of the once-daily human glucagon-like peptide-1 analogue liraglutide should be modified in patients with renal impairment has not previously been studied.
What this study adds: * Renal dysfunction was not found to increase the exposure of liraglutide. * Hence, no dose adjustment is expected to be required in patients with Type 2 diabetes and renal impairment treated with liraglutide.
Aims: To investigate whether dose adjustment of the once-daily human glucagon-like peptide-1 analogue liraglutide is required in patients with varying stages of renal impairment.
Methods: A cohort of 30 subjects, of whom 24 had varying degrees of renal impairment and six had normal renal function, were given a single dose of liraglutide, 0.75 mg subcutaneously, and completed serial blood sampling for plasma liraglutide measurements for pharmacokinetic estimation.
Results: No clear trend for change in pharmacokinetics was evident across groups with increasing renal dysfunction. While the between-group comparisons of the area under the liraglutide concentration-curve (AUC) did not demonstrate equivalence [estimated ratio AUC(severe)/AUC(healthy) 0.73, 90% confidence interval (CI) 0.57, 0.94; and AUC (continuous ambulatory peritoneal dialysis)(CAPD)/AUC(healthy) 0.74, 90% CI 0.56, 0.97], the regression analysis of log(AUC) for subjects with normal renal function and mild-to-severe renal impairment showed no significant effect of decreasing creatinine clearance on the pharmacokinetics of liraglutide. The expected AUC ratio between the two subjects with the lowest and highest creatinine clearance in the study was estimated to be 0.88 (95% CI 0.58, 1.34) (NS). Degree of renal impairment did not appear to be associated with an increased risk of adverse events.
Conclusions: This study indicated no safety concerns regarding use of liraglutide in patients with renal impairment. Renal dysfunction was not found to increase exposure of liraglutide, and patients with Type 2 diabetes and renal impairment should use standard treatment regimens of liraglutide. There is, however, currently limited experience with liraglutide in patients beyond mild-stage renal disease.
Figures
Similar articles
-
Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide.Br J Clin Pharmacol. 2010 Dec;70(6):807-14. doi: 10.1111/j.1365-2125.2010.03762.x. Br J Clin Pharmacol. 2010. PMID: 21175436 Free PMC article. Clinical Trial.
-
The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.Adv Ther. 2011 Mar;28(3):213-26. doi: 10.1007/s12325-010-0110-x. Epub 2011 Feb 17. Adv Ther. 2011. PMID: 21340616 Clinical Trial.
-
Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.Int J Clin Pharmacol Ther. 2008 Jun;46(6):273-9. doi: 10.5414/cpp46273. Int J Clin Pharmacol Ther. 2008. PMID: 18541123 Clinical Trial.
-
A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.Clin Ther. 2009 Nov;31(11):2472-88. doi: 10.1016/j.clinthera.2009.11.034. Clin Ther. 2009. PMID: 20109994 Review.
-
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics.Clin Pharmacokinet. 2016 Jun;55(6):657-72. doi: 10.1007/s40262-015-0343-6. Clin Pharmacokinet. 2016. PMID: 26597252 Free PMC article. Review.
Cited by
-
The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function.Sci Rep. 2024 Feb 29;14(1):5002. doi: 10.1038/s41598-024-55724-z. Sci Rep. 2024. PMID: 38424466 Free PMC article.
-
Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes.J Clin Med. 2023 Jun 8;12(12):3925. doi: 10.3390/jcm12123925. J Clin Med. 2023. PMID: 37373620 Free PMC article. Review.
-
Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs.Kidney Int Rep. 2022 Aug 3;7(11):2345-2355. doi: 10.1016/j.ekir.2022.07.167. eCollection 2022 Nov. Kidney Int Rep. 2022. PMID: 36531884 Free PMC article.
-
Tirzepatide: A New Generation Therapeutic for Diabetes Type 2.Endocr Metab Immune Disord Drug Targets. 2023;23(8):1046-1050. doi: 10.2174/1871530322666221004151212. Endocr Metab Immune Disord Drug Targets. 2023. PMID: 36200219 Free PMC article. Review.
-
Clinical Analysis of the Renal Protective Effect of GLP-1 on Diabetic Patients Based on Edge Detection.J Healthc Eng. 2022 Mar 22;2022:6504006. doi: 10.1155/2022/6504006. eCollection 2022. J Healthc Eng. 2022. PMID: 35360475 Free PMC article.
References
-
- Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes: UK Prospective Diabetes Study 74. Diabetes. 2006;55:1832–9. - PubMed
-
- Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64) Kidney Int. 2003;63:225–32. - PubMed
-
- Parving H-H, Østerby R, Ritz E. Diabetic nephropathy. In: Brenner BM, editor. The Kidney. 6th. Philadelphia, PA: W.B. Saunders; 2000. pp. 1731–73.
-
- Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118:577–81. - PubMed
-
- Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitch WE, Hirschman GH, Myers BD. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med. 1996;335:1636–42. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous